Peginterferon Alfa-2A

• Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy… Pending
  2024-518216-39-00 Phase II 1 country Region Sjaelland
• A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting
  2024-516109-21-00 Phase III 1 country The University Of Birmingham
• Effect of low-dose Interferon-alfa2a on perioperative immune suppression Recruiting
  2024-517619-65-00 Phase II 1 country Region Sjaelland
• Observational Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Patients with Chronic hepatitis D Recruiting
  2023-504414-29-00 Phase III/IV 1 country Karolinska University Hospital
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Ended
  2023-504865-21-00 Phase III 10 countries Merck Sharp & Dohme LLC
• KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended
  2024-513912-89-00 Phase II/III 13 countries Kartos Therapeutics Inc.
• Study of immunological activity after personalized immunomodulatory therapy regulating the Th17 pathway in patients with extramembranous glo… Ended
  2023-503226-39-00 Phase II 1 country Centre Hospitalier Universitaire De Nice
• A Study to Evaluate Investigational Therapies in Chronic Hepatitis B Virus Infection Ended
  2024-513176-17-00 Phase II 2 countries Vir Biotechnology Inc.
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi… Ended
  2024-513177-48-00 Phase II 2 countries Vir Biotechnology Inc.
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended
  2024-511972-33-00 Phase III 10 countries Celgene Corp.

Showing 1–10 of 10 trials